Delving into the Latest Updates on Peptinov SAS with Synapse

Overview

Basic Info

Introduction

Peptinov SAS is a French corporation headquartered in Paris that specializes in creating immunotherapy treatments for chronic inflammatory diseases. The company was established in 2009 by Jean-François Zagury .

Tags

Skin and Musculoskeletal Diseases

Immune System Diseases

Nervous System Diseases

Synthetic peptide vaccine

Recombinant polypeptide

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Immune System Diseases	2
Nervous System Diseases	1
Neoplasms	1

Top 5 Drug Type	Count

Antibody	1
Small molecule drug	1
Synthetic peptide vaccine	1
Recombinant polypeptide	1

Top 5 Target	Count

IL-6(Interleukin-6)	1
TNF x TNF-α	1

PPV-06 targets interleukin-6, a key molecule implicated in many inflammatory diseases such osteoarthritis. PPV-06 is used to induce the production of antibodies directed against IL-6. The antibodies produced will neutralize the interleukine-6 involved in the body's inflammatory process.
The goal of this clinical trial is to test the safety and efficacy of PPV-06 in participants with Knee Osteoarthritis. The main questions are to evaluate if PPV-06 can reduce pain and improve functioning in participants with knee osteoarthritis, and to evaluate if ¨PPV-06 is safe when administered to participants.
Participants will be administered with 6 subcutaneous injections of either PPV-06 or placebo, over a two-year period.

Start Date01 Dec 2024

Sponsor / Collaborator

Peptinov SAS

NCT04447898 / CompletedPhase 1

A Randomized, Double-blind, Placebo-controlled, Dose Escalation Phase I Study Assessing the Safety and Immune Response of PPV-06 Vaccine in Patient With Inflammatory Knee Osteoarthritis (KOA)

PPV-06 immunotherapy targets interleukin-6 (IL-6), a key molecule of the immune system whose overproduction is implicated in many inflammatory and autoimmune diseases such as rheumatoid arthritis and osteoarthritis. The benefit of vaccination with PPV-06 is to induce, in response to immunizations, the production of antibodies directed against IL-6. The antibodies produced will neutralize the biological activity of IL-6 involved in the body's inflammatory process.
The primary objective is to evaluate the safety/tolerability of vaccination with PPV-06.

Start Date18 Feb 2021

Sponsor / Collaborator

Peptinov SAS

100 Clinical Results associated with Peptinov SAS

Login to view more data

0 Patents (Medical) associated with Peptinov SAS

Login to view more data

100 Deals associated with Peptinov SAS

Login to view more data

100 Translational Medicine associated with Peptinov SAS

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

2

Preclinical

Phase 2 Clinical

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Anti-IL-6 vaccine(Peptinov) ( IL-6 )	Osteoarthritis, Knee More	Phase 2
Cibles immuno-oncologie - Cancer(Peptinov)	Neoplasms More	Preclinical
SPD-304 ( TNF x TNF-α )	Inflammation More	Preclinical
Pain (Peptinov)	Pain More	Discovery